Hubro Therapeutics strengthens its leadership with the assignment of Mr. Geir Hetland as Chief Financial Officer.

Hubro Therapeutics is pleased to announce that Mr. Geir Hetland will take on the position as CFO of the company effective from early 2023. Mr. Hetland transits from position as CFO at Thermo Fisher Scientific (previously Dynal Biotech) in Norway. Mr. Hetland brings an extensive background from the biotechnology industry in the EU and US. Mr. Hetland has previously held positions as CFO of AstraZeneca and has broad experience including finance, budget planning, marketing operations, integration and strategic planning. Mr. Hetland will join the company’s executive leadership group.

This website uses cookies to ensure you get the best experience on our website.